Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07301515Not ApplicableCompleted

Randomised Controlled Trial of an Antioxidant and Sunscreen Combination Cream for Reducing DNA Damage in Human Skin

Role: collaborator

NCT06654999Completed

How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.

Role: lead

NCT05126173Completed

DERM US and EU Validation Study

Role: lead

NCT04116983Completed

DERM NMSC Validation Study

Role: lead

NCT04123678Completed

DERM Health Economics Study

Role: lead

NCT02612168Not ApplicableCompleted

Melanoma Image Analysis Algorithm (MIAA) Validation Study

Role: lead

All 6 trials loaded